Generic Drug Manufacturer Hikma Providing Credits for 340B Overcharges

Hikma Pharmaceuticals USA, the U.S. division of U.K.-based generic drug manufacturer Hikma Pharmaceuticals plc, is crediting 340B covered entities for overcharges on a long list of NDCs from the fourth quarter of 2017 through the fourth quarter of 2020.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content

*Sign up for news summaries and alerts from 340B Report